A Phase 3 interventional study of Aficamten in Obstructive Hypertrophic Cardiomyopathy, sponsored by Corxel Pharmaceuticals. Completed at 12 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Corxel Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic — 2 open to participants now, 5 under way, 4 of them phase 3. aficamten · Cardiomyopathy, Hypertrophic.
Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, this one is the 8th largest by enrollment, is one of 3 that started in 2023, is one of 5 in phase 3, and was the 8th registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →2 of the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic are open now, in 12 countries. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States
Ages 18–90
Cytokinetics · Sites in United States, Argentina, Australia and 16 more countries
Ages 18–85
By country, each count listing its studies:
aficamten: first FDA approval 2025 (MYQORZO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 7 · Phase 4 1
First in 2018; this study’s year is marked. 3 started in 2023.
This study's enrollment of 40 is below the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 96 across the 11 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 4 most frequent:
Corxel Pharmaceuticals is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Corxel Pharmaceuticals has 2 studies filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
1 of the studies testing aficamten in Cardiomyopathy, Hypertrophic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07600177Oregon Health and Science UniversityMavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, including assessments of cardiac function and steady-state Pharmacokinetics (PK) during chronic dosing with aficamten.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this arm take daily dose of Aficamten. Each patient will start at the lowest dose (5 mg) in the pre-specified dose range and undergo dose titration up to a maximum of 20 mg.
Drug: Aficamten
5-20mg
Also known as: CK-3773274
Patient incidence of reported adverse events (AEs)
Time frame: Baseline to End of study, up to 2 years
Patient incidence of reported serious adverse events (SAEs )
Time frame: Baseline to End of study, up to 2 years
Patient incidence of LVEF<50% & LVEF <40%
Time frame: Baseline to End of study, up to 2 years
Peak LVOT-G at rest and with Valsalva provocation
Time frame: Change from baseline values to week 48 at 12-week intervals;
Proportion of patients with resting LVOT-G <50 mmHg
Time frame: Change from baseline values to week 48 at 12-week intervals;
Proportion of patients with resting LVOT-G <30 mmHg
Time frame: Change from baseline values to week 48 at 12-week intervals;
Proportion of patients with post-Valsalva LVOT-G <50 mmHg
Time frame: Change from baseline values to week 48 at 12-week intervals;
Proportion of patients with post-Valsalva LVOT-G <30 mmHg
Time frame: Change from baseline values to week 48 at 12-week intervals;
Proportion of patients with LVEF ≥50%, resting LVOT-G <30 mmHg, and post-Valsalva LVOT-G <50 mmHg
Time frame: Change from baseline values to week 48 at 12-week intervals;
First resting LVOT-G <50 mmHg
Time frame: Time to the following event through last follow-up, up to 2 years.
First resting LVOT-G <30 mmHg
Time frame: Time to the following event through last follow-up, up to 2 years.
First post-Valsalva LVOT-G <50 mmHg
Time frame: Time to the following event through last follow-up, up to 2 years.
First post-Valsalva LVOT-G <30 mmHg
Time frame: Time to the following event through last follow-up, up to 2 years.
First LVEF ≥50%, resting LVOT-G <30 mmHg, and post-Valsalva LVOT-G <50 mmHg
Time frame: Time to the following event through last follow-up, up to 2 years.
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2023 to primary completion in Oct 2025, 23 months.
Of 15 phase 3 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 23 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aficamten
Cardiomyopathy, Hypertrophic →
Corxel Pharmaceuticals